Phase I Evaluation of ΔvirG Shigella sonnei Live, Attenuated, Oral Vaccine Strain WRSS1 in Healthy Adults

We conducted a phase I trial with healthy adults to evaluate WRSS1, a live, oral ΔvirG Shigella sonnei vaccine candidate. In a double-blind, randomized, dose-escalating fashion, inpatient volunteers received a single dose of either placebo (n = 7) or vaccine (n = 27) at 3 × 10(3) CFU (group 1), 3 ×...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kotloff, Karen L., Taylor, David N., Sztein, Marcelo B., Wasserman, Steven S., Losonsky, Genevieve A., Nataro, James P., Venkatesan, Malabi, Hartman, Antoinette, Picking, William D., Katz, David E., Campbell, James D., Levine, Myron M., Hale, Thomas L.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2002
Materias:
Microbial Immunity and Vaccines
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC127867/
https://ncbi.nlm.nih.gov/pubmed/11895966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/IAI.70.4.2016-2021.2002
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares